The VARC (Valve Academic Research Consortium) for transcatheter aortic valve replacement set the standard for selecting appropriate clinical endpoints reflecting safety and effectiveness of transcatheter devices, and defining single and composite clinical endpoints for clinical trials. No such standardization exists for circumferentially sutured surgical valve paravalvular leak (PVL) closure. This document seeks to provide core principles, appropriate clinical endpoints, and endpoint definitions to be used in clinical trials of PVL closure devices. The PVL Academic Research Consortium met to review evidence and make recommendations for assessment of disease severity, data collection, and updated endpoint definitions. A 5-class grading scheme to evaluate PVL was developed in concordance with VARC recommendations. Unresolved issues in the field are outlined. The current PVL Academic Research Consortium provides recommendations for assessment of disease severity, data collection, and endpoint definitions. This article is being published concurrently in European Heart Journal. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article. 
CORE PRINCIPLES I: CLINICAL
PVLs of varying clinical significance are detected in 5% to 18% of all implanted surgical valves, with an incidence of 2% to 10% in the aortic position and 7% to 17% in the mitral position (5-7). Risk factors for PVL development include: annular calcification, tissue friability, prior endocarditis, or other inflammatory processes and recent initiation of corticosteroid therapy (8) (9) (10) (11) . Multiple procedural factors may increase the risk of PVL: implantation type (mechanical implants are a greater risk than bioprosthetic implants), position (supra-annular prostheses are a greater risk than annular aortic prostheses), and surgical technique (continuous sutures are a greater risk than interrupted sutures for mitral prostheses) (6, 7) .
A majority (74%) of PVL occurs within the first year of valve implantation (12) . Late PVL is commonly related to suture dehiscence associated with infective endocarditis or the gradual resorption of annular calcifications that are not completely debrided (13) . Percutaneous PVL repair offers an alternative to traditional surgery, especially for patients who are considered to be at high surgical risk (14) . Two large single-center studies involving 57 and 141 patients with PVL, respectively, reported overall success rates for percutaneous PVL of 77% to 86.5%, and clinical success ranging from 67% to 77% (15, 16) . A recent Bayesian meta-analysis, using cardiac mortality as a primary endpoint, evaluated 12 clinical studies involving 362 patients (17) . Following PVL closure, improvement in heart failure (HF) symptoms is typically limited to patients with no or mild residual regurgitation (18) . Patients with hemolytic anemia may not improve following PVL closure. Hein et al. (19) observed that 33% of patients with transfusion-requiring hemolysis had worsening hemolysis after transcatheter-attempted closure, and there was newly developed hemolysis in 10% of all patients. Persistent hemolytic anemia after attempted PVL closure predicts poor survival and need for cardiac surgery (20) . A recent singlesite study of the effect of changes in procedural technique, use of advanced imaging modalities (i.e.,
3-dimensional [3D] echocardiography), and device choice (smaller nitinol braided devices) on outcomes
showed a significant learning curve effect on procedure and fluoroscopy time, complications (30-day major adverse cardiovascular events), and hospital length of stay (21) . The predominant mechanism of device failure in this study was bioprosthetic leaflet impingement, highlighting the need for defectspecific devices.
The current American College of Cardiology (ACC)/ American Heart Association (AHA) indications for percutaneous PVL repair include patients with prosthetic valves and symptomatic HF (NYHA functional class III to IV) and persistent hemolytic anemia, who have anatomic features that are suitable for percutaneous surgery in centers of expertise (14) .
Closure of less-severe PVL remains controversial.
Percutaneous repair is contraindicated in patients with active endocarditis or significant dehiscence involving more than one-fourth to one-third of the valve ring (22).
CLINICAL PRESENTATION AND RISK ASSESSMENT
OF PVL. Approximately 2% to 5% of PVL are clinically relevant, and are associated with complications of congestive HF, hemolytic anemia, and infective endocarditis (5, 11, 23) . Most PVLs are small and asymptomatic; however, approximately 90% of patients with symptomatic leaks typically present with congestive HF (13, 22) , which can be precipitated or worsened by anemia (13) . Hemolytic anemia resulting from shear stress on the red blood cells is the second most common presentation of PVL, affecting one-third to three-quarters of patients with symptomatic PVL (8, 13) . Symptoms of anemia can be severe and may require transfusion, and patients may experience poor quality of life (QOL) (24, 25) .
PVL can also increase the risk for infectious endocarditis (26).
Mortality rates of 7% to 11% have been observed in contemporary single-site studies among those (27, 28) , and reports of perioperative complications (e.g., infection, stroke, and myocardial infarction) appear higher for surgical repair than for percutaneous closure (29).
However, a direct comparison of closure techniques has never been performed. Surgical risk may be especially high in patients with PVL who are severely symptomatic and have significant comorbidities (8) , or in whom dehiscence involves a substantial portion of the sewing ring (30) . After attempted transcatheter PVL closure, residual leak of moderate degree or more is associated with a higher risk of need for cardiac surgery or of death (18) .
The Society of Thoracic Surgeons risk score and the EuroSCORE II system are widely used for surgical risk evaluation in cardiac surgery; however, such scores have been validated only in standard surgical-risk patients (3), and they may fail to adequately capture risk factors for patients undergoing PVL closure.
These factors must be considered by the heart team when deciding on the appropriateness of intervening. Table 2 summarizes the studies supporting the proposed post-procedural evaluation.
Current guidelines suggest an initial transthoracic echocardiogram (TTE) be performed 6 weeks to 3 months after valve implantation to assess the effects of surgery and to serve as a baseline for comparison (14) . For bioprosthetic valves, routine echocardiographic surveillance is considered appropriate $3 years after implantation if there is no known or suspected valve dysfunction (31) . It is the opinion of the writing group that after the initial baseline postoperative evaluation, which would include imaging and laboratory testing, yearly follow-up is necessary to better characterize the true prevalence of PVL and its consequences, such as hemolysis. After PVL closure, yearly follow-up assessment is also indicated to determine continued safety and efficacy. A comprehensive evaluation would include clinical and functional assessment (i.e., with echocardiography), as well as laboratory evaluation of hemolysis. The role of routine assessment of biomarkers has not been studied.
CORE PRINCIPLES II: DIAGNOSTIC TESTING FOR ASSESSMENT OF LOCATION AND SEVERITY OF PVL
A variety of diagnostic tests should be performed to determine whether regurgitation following prosthetic valve replacement is functional or abnormal and, if abnormal, whether it is central or paravalvular and the regurgitant severity. Echocardiography is the diagnostic test of choice for assessment of prosthetic valve function; however, several imaging modalities, each with its own individual merits ( Table 2) , can be used to assess the spatial and anatomic dimensions of PVL in surgical prosthetic valves (14, 32) (Online Table 3 (mild, moderate, severe) and the angiographic 4-class scheme to report the severity of prosthetic regurgitation, these schemes have many pitfalls, and intermediate grades may not be reliably estimated (40, 41) .
A unifying 5-class scheme for PVL regurgitation severity following transcatheter AVR has recently been proposed to improve communication between members of the heart team, resolve differences between grading schemes, and align echocardiographic parameters with clinically-used terminology, and is recommended by the writing group for clinical trials (42) . The proposed 5-class schemes for aortic ( Table 3) and mitral ( Table 4 ) PVL provide a mechanism for systematic study of PVL outcomes, and a means for correlating outcomes with prior grading schemes.
Importantly, this proposed grading scheme is not intended to replace existing guidelines, but could be used as the initial grading scheme and then collapsed into the 3-class scheme for reporting and/or outcomes analysis. A suggested hierarchy of parameters is summarized in Figure 2 for prosthetic aortic PVL and none/trace (RF #15%), mild (16% to 29%), and moderate/severe ($30%) (43) . By ROC analysis, a regurgitant fraction of $30% best identified patients at greatest risk for 2-year mortality and the composite of mortality and rehospitalization for HF. These results, together with the echocardiographic outcomes from the PARTNER II SAPIEN 3 trial, using the granular grading scheme showing increased mortality associated with moderate or greater PVL (44) not only help validate the cutoffs for PVL severity in Table 3 , but also support the use of the unifying grading scheme nomenclature (42) . D i r e c t p l a n i m e t r y o f v e n a c o n t r a c t a a r e a . Offline analysis of 3D color Doppler volumes can be used to planimeter the PVL vena contracta area and accurately measure the dimensions of the regurgitant jet, with a 3D color regurgitant orifice major *Parameters that are most frequently used to grade PVL severity by Doppler echocardiography. †Care must be taken to avoid over gaining or incomplete spectral traces (i.e., when the jet moves in and out of the Doppler beam). ‡Parameters that are less often applicable due to pitfalls in the feasibility/accuracy of the measurements or to the interaction with other factors. §Applies to chronic PVL but is less reliable for periprocedural/early post-procedural assessment. kThese parameters should not be used in patients with eccentric or multiple jets. ¶These parameters are influenced by heart rate, LV, and aortic compliance. #Regurgitant volume is calculated as the difference of stroke volume measured in the LV outflow tract minus the stroke volume measured in the right ventricular outflow tract. **The effective regurgitant orifice area is calculated by dividing the regurgitant volume by the time velocity integral of the AR flow by CW Doppler. † †There are important variabilities in the cutpoint values of regurgitant fraction and volume to grade AR by CMR in published reports.
CMR ¼ cardiac magnetic resonance; CW ¼ continuous wave; LVOT ¼ left ventricular outflow tract; PHT ¼ pressure half-time; PW ¼ pulsed wave; other abbreviations as in Tables 1 and 2. diameter $0.65 cm consistent with greater than moderate PVL (49) . Outcomes based on these parameters will require further study. Although 2D imaging may accurately locate defects and measure radial dimensions, the circumferential extent of the defect is best imaged with 3D TEE (50) .
Similarly, the regurgitant orifice area can be planimetered on noncolor 3D images (51); however, confirmation by both 2D and 3D color Doppler *Parameters that are most frequently used to grade regurgitation severity by Doppler echocardiography. †>15 of sewing ring motion that is not consistent with normal phasic motion of the mitral annulus. ‡Parameters that are less often applicable due to pitfalls in the feasibility/accuracy of the measurements or to the interaction with other factors. §For bileaflet mechanical valve, E velocity >1.9 m/s is abnormal. kPHT should not be used to calculate valve area in the setting of a prosthetic valve; however, it should be normal in the absence of significant stenosis. ¶Care must be taken to avoid over gaining or incomplete spectral traces (i.e., when the jet moves in and out of the Doppler beam). #Pulmonary vein flow reversal may be influenced by LV systolic and diastolic function, LA size and pressure, atrial arrhythmias, and the presence of mitral inflow obstruction; however, holosystolic flow reversal is specific for severe mitral regurgitation. **Regurgitant volume is calculated as the difference of stroke volume measured in the LV outflow tract minus 2D-derived (total) LV stroke volume. Ruiz et al.
native aortic regurgitation (AR) (14) . Finally, echocardiographic imaging may detect cavitation bubbles, which are frequently seen with normal prosthetic valve function (58) . A large number of bubbles may be an indication of hemolysis and be correlated with levels of lactate dehydrogenase (LDH) (59) . printing of CT data is also increasingly feasible (68), facilitating the understanding of the defect. The adjudication of events should not be limited to the acute procedure period (30 days), but also, when appropriate, longer periods (e.g., death months after a disabling stroke due to the procedure).
C M R i m a g i n g f o r a s s e s s m e n t o f p r o s t h e t i c v
AE ENDPOINTS. M o r t a l i t y . Mortality for PVL procedures should be divided into all-cause and cardiovascular mortality. As with other ARC definitions, data on immediate procedural mortality and procedural mortality should also be gathered (Table 5) Table 6 . Brain imaging is often performed for evaluation of stroke, typically using modalities such as CT for acute hemorrhage, as well as for acute, subacute, and chronic infarction. Magnetic resonance imaging is more sensitive for acute infarction, and can also identify chronic ischemia, as well as both acute and chronic hemorrhage. Imaging as a stand-alone entity should not be used to diagnose a stroke; the diagnosis should be made in conjunction with clinical assessment, preferably by a neurologist. Primary endpoints. All strokes (ischemic and hemorrhagic) and transient ischemic attacks should be reported as endpoints, as defined in Table 6 . Secondary endpoints. Functional outcome should be a secondary endpoint of the investigation. The modified Rankin Scale is often used for this purpose (93) .
Functional outcome should be assessed and documented by a certified provider at all scheduled visits in the trial, and at 90 days after stroke onset, as well as at the trial's end of follow-up. Disabling stroke is another secondary endpoint that is usually defined at 90 days from symptom onset ( Table 6) . Table 10 ).
The access site includes any location (arterial or venous) traversed by a guidewire, catheter, or sheath (including the LV apex). Access-related is defined as PVLARC recommends definitions for several other endpoints ( Table 11) . Percutaneous closure device failure Failure of a closure device to achieve hemostasis at the arteriotomy site leading to alternative treatment (other than manual compression or adjunctive endovascular ballooning) Before a trial can be properly designed, the PVL study group must be carefully defined, the clinical question to be addressed should be precisely identified, the 
